Abstract
The risk of overwhelming healthcare systems from a second wave of COVID-19 is yet to be quantified. Here, we investigate the impact of different reopening scenarios of states around the U.S. on COVID-19 hospitalized cases and the risk of overwhelming the healthcare system while considering resources at the county level. We show that the second wave might involve an unprecedented impact on the healthcare system if an increasing number of the population becomes susceptible and/or if the various protective measures are discontinued. Furthermore, we explore the ability of different mitigation strategies in providing considerable relief to the healthcare system. The results can aid healthcare planners, policymakers, and state officials in making decisions on additional resources required and on when to return to normalcy.
One Sentence Summary A second wave of COVID-19 will have an unprecedented impact on the healthcare system.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for this study was in part provided by the cooperative agreement 70NANB15H044 between the National Institute of Standards and Technology (NIST) and Colorado State University. The content expressed in this paper are the views of the authors and do not necessarily represent the opinions or views of NIST or the U.S Department of Commerce.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The authors declare that they have no competing interests.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in the analysis are included in the paper and the Supplementary Materials. Additional data related to this paper may be requested from the corresponding author. The disease transmission model components have been described in the paper and the Supplementary Materials and will be made available from the corresponding author on request.
